In addition to its well-known homoeostatic actions in the cardiovascular system, ET-1 has been shown to constitute a potent growth regulatory peptide in various tissues. We have studied the expression of ET-1 and its receptors (ETAr and ET-Br) in human meningiomas (n = 35) as well as their involvement in cellular growth. By PCR of reversetranscribed RNA we detected ET-1 mRNA in 91% (32 of 35), ET-Ar mRNA in 82% (29 of 35), and ET-Br mRNA in 42% (15 of 35) of human meningiomas examined. The localization of ET-1 mRNA, ET-Ar mRNA, and ET-1 peptide in tumoral cells was observed by in situ hybridization and immunohistochemistry, whereas ET-Br mRNA was expressed at low level only in cells belonging to blood vessels. In addition, we found that ET-1 stimulated [3H]thymidine incorporation in primary cell cultures of 20 meningiomas and that this effect could be blocked by BQ-123, a specific antagonist for ET-Ar. In contrast, RES-701-3, an antagonist of ET-Br, did not block the proliferative effect of ET-1. In conclusion, our data provide evidence that ET-1 constitutes an important growth factor for meningiomas acting via ETAr. We can hypothesize that ET-1, acting in concert with other growth factors and cytokines, is involved in the meningioma tumorigenesis. (J. Clin.
Introduction
Originally isolated by Yanagisawa in 1988 from culture media of vascular endothelial cells ( 1 ), endothelin (ET)' is comprised of three different peptides: ET-1, ET-2, and ET-3 (2) . Two human ET receptors have been cloned and pharmacologically characterized: the isopeptide-selective ET-A receptor (ET-Ar) which preferentially binds ET-1 (3) and which is specifically antagonized by BQ-123 (4) , and the ET-B receptor (ET-Br) which is known to bind ET-1, ET-2, and ET-3 with the same affinity (5) .
In addition to their well known homoeostatic and compensatory actions in the cardiovascular system (for review see reference 6), ETs were identified in various areas of human (7) and rat brain (8) , mainly in glial cells (9, 10) , acting as modulators of brain functions (for review see reference 11). Moreover, ET-1 has been described to exert a role in the promotion of mitogenesis in normal and tumoral tissues (for review see reference 12). has been shown to stimulate protooncogene expression and growth of fibroblasts (13), endothelial cells (14) , and vascular smooth muscle cells (15) . Furthermore, the expression and release of ET-1 in human cancer cell lines (16, 17) and in human tumors (18) (19) (20) suggest a potential role for ET-1 in tumoral growth promotion or maintenance.
An abnormal expression of growth factors or their receptors has been associated with the development of human and animal tumors (21) . There is clear evidence that an intratumoral production of growth factors, operating in an autocrine/paracrine manner, may be involved in neoplastic transformation. A growing number of reports have already documented the presence of EGF (22, 23) , IGF I and 11 (24) , bFGF (25) , TGFa (26) , PDGF (27) , and their receptors in different types of primary intracranial tumors such as differentiated and undifferentiated gliomas and meningiomas. Receptors for ETs have been found in human gliomas (28) , and our group has shown recently that ET-1 immunoreactivity is absent in normal human anterior pituitary but is expressed in 50% of human pituitary adenomas examined (29) .
McCumber (8) described moderate levels of ET-1 expression and ET-1 binding sites in meninges of 19-d rat fetus. Since growth factors have been described to play a role in fetal and neonatal development as well as in neoplastic progression (30), we have investigated whether ET-1 and its receptors are expressed in human meningiomas and normal human meninges. We have also examined whether ET-1 plays a role in the growth of human meningiomas in culture. (36) . In brief, 10-,um sections of 24 meningiomas were fixed in 4% phosphatebuffered paraformaldehyde and stored in ethanol at 4°C until use. Two different deoxyoligonucleotides complementary to the mRNAs for human pre-pro-ET-1, ET-Ar, or ET-Br were synthesized (Table I ). The two oligos for ET-Br recognized both splice variants (37) . Deoxyoligonucleotides were 3'-end labeled with a_-35S-dATP (Dupont, Bad Homburg, Germany) (molar ratio 1:30) by terminal transferase (Boehringer Mannheim). Unincorporated nucleotides were removed by Bio-Spin 6 columns (Bio-Rad, Munich, Germany) and 2 Ml of 1 M DTT was added.
After rehydration in PBS and a passage into 0.25% acetic anhydride in 0.1 M triethanolamine-HCl pH 8 .0/0.9% NaCl for 10 min, sections were dehydrated in ethanol and finally air dried. Each section was hybridized for 16-20 h at 42°C with a solution containing 50,000-200,000 cpm of radioactive probe, 50% deionized formamide, 4 X SSC, 10% dextran sulfate, 100 Mg/ml polyadenylic acid, 5 X Dehnardt's, 25 mM sodium phosphate, pH 7.0, 1 mM sodium pyrophosphate, and 200 qg/ml salmon sperm DNA. After consecutive washes in 1 x SSC for 10 min at room temperature (rt), 1 x SSC for 30 min at 55°C, 1 x SSC, 0.1 X SSC for 1 min each at rt and dehydration in ethanol, slides were dipped in Ilford K5 photoemulsion. After exposure of 6-8 wk, slides were developed in Kodak D-19 and fixed and counterstained with 0.5% cresylviolet. To control the specificity of the hybridization signal, a 100-fold excess of nonlabeled oligonucleotides was added to the radioactive probe and applied to the adjacent section. The specificity of all six ISH oligonucleotide probes was controlled by Northern blot analysis on human lung mRNA.
IHC. Two antibodies (Ab) for ET-1 were used: a rabbit polyclonal (Peninsula, Heidelberg, Germany) and a mouse mAb (Dianova, Hamburg, Germany) (crossreactivity for ET-3: 7 and 2%, respectively). From Dako (Hamburg, Germany) were mouse mAb for epithelial mem- brane antigen (EMA), a marker for meningioma tumoral cells (38) , rabbit and swine serum, biotinylated swine anti-rabbit and rabbit antimouse IgGs. IHC was performed with minor modifications as described previously (29) . In brief, after deparaffination and blockade of endogenous peroxidase with 0.25% KMnO4, sections (5 Jim) were preincubated in rabbit or swine serum (1:10) followed by application of polyclonal or monoclonal ET-1 Ab (1:800-1:3,000 and 1:100-1:200) or EMA Ab (1:50-1:150) overnight at 4°C. After incubation with the respective biotinylated IgGs ( 1:300) and the streptavidin-biotin-horseradish peroxidase complex (1:100) (Fig. 1, A-C) . Tissues in which we were not able to detect ET-1, ET-Ar, or ET-Br mRNA were screened for f3-actin mRNA expression using the same method. All tissues assayed in this way showed a positive signal for /-actin mRNA (data not shown) demonstrating that negative ET results by RT-PCR were not due to a degradation of mRNA.
The specificity of RT-PCR amplification products for ET-1, ET-Ar, and ET-Br was confirmed by Southern blot (Fig. 2 (Fig. 3, a and b) . The (Fig. 4 a) .
In comparison with ET-1 mRNA, the hybridization signals for ET-Ar mRNA found in the meningiomas tested were more intense. At the microscopic level, a dense accumulation of silver grains, identifying ET-Ar mRNA, was seen over the majority of cells in all areas of the tumors (Fig. 3 c and d) . In contrast to the strong hybridization signal in meningiomas, no signal for ET-Ar mRNA was found in normal meninges (Fig. 4 b) .
Oligonucleotides for ET-Br mRNA showed hybridization signals only in cells belonging to blood vessels (Fig. 3, e and  f ) . ET-Br mRNA was not detectable in normal meninges (Fig.   4 c) .
The two different oligonucleotides used for the detection of ET-1, ET-Ar, or ET-Br mRNAs showed the same topographical localization of hybridization signals for each mRNA on adjacent sections, confirming that the sequences chosen were specific. Another confirmation of specificity of all six oligonucleotides for ISH was obtained by Northern blot analysis on human lung mRNA (data not shown). Hybridization with both oligos for ET-Ar mRNA showed completely different signal patterns in comparison with those for ET-Br, proving that there was no mutual crosshybridization between them.
Expression of ET-I-like immunoreactivity in meningiomas and normal meninges. In 10 meningiomas, in which ET-1 mRNA was detected by RT-PCR and ISH, we also studied the expression of ET-1 at the protein level. By IHC, ET-1 protein (Fig. 5, b, d , f and h) or preincubating the antisera with an excess of ET-1 peptide, no staining for ET-1 was observed. ET-1 was found not only in cells constituting the tumor, but could also be detected in collagenous elements and occasionally in some cells lining vessels which were presumably endothelial cells. Psammoma bodies, which are frequently seen in transitional and dominating in psammomatous meningiomas, were also stained for ET-I (Fig.  5 g ). There was no apparent correlation between the different histological types and the intensity of ET-l staining. Normal human leptomeninges showed only a scattered distribution of cells positive for ET-1-like immunoreactivity (Fig. 4 d) . Only the meningeal layer of normal human pachymeninges exhibited diffuse immunostaining for ET-1 (Fig. 4 f ) . No staining for ET-1 was observed in adjacent sections in absence of the first antibody (Fig. 4, e and g ). Positive staining in large vessels of the brain confirmed the specificity of the ET-1 Abs (data not shown).
Immunoreactivity for EMA in meningiomas. All meningiomas showed an intense immunoreactivity for EMA (data not shown). Groups of cells, positive for ET-1 mRNA, ET-Ar mRNA, or ET-1-like immunoreactivity, were identified as being positive for EMA staining in adjacent sections. BrdU fluorescence staining clearly demo poration was nuclear (Fig. 8 b) ( Fig. 8 a) . Moreover, In the brain, ET-1 expression has been demonstrated in instrated that the incorendothelial cells of medium-and large-diameter cerebral and -ove which of the two arachnoidal blood vessels (7) . Since ET-1 is found in vascular imulated proliferation, endothelium, this peptide is thought to participate in the angio--sence of selective ETgenesis occurring during the establishment of the neoplasia in cific ET-Ar antagonist, vivo in concert with other angiogenic agents (48) . Thus, ETcentrations of 10-6 M 1 might be involved in the tumorigenesis of well vascularized n Fig. 7) . In contrast, brain tumors, such as gliomas (28, 49) tion causes severe craniofacial deformities in the organs developed from the pharyngeal arches, whose origin is mainly from neural crest-derived ectomesenchymal cells (50) . ET-1 is also involved in the human fetal development of neural crest-derived craniofacial tissues (51) . Since the neural crest gives rise to the pia mater and arachnoid (52, 53) , an autocrine/paracrine action of ET-1 via type A receptor seems to be important in fetal development. ET-1 may also-play a role in the development of tumors deriving from the same embryological origin similar to what has already been described for other growth factors (30).
The abnormal expression of various growth factors and/or their receptors has been shown to be involved in the pathogenesis of tumors. Our data prompt us to hypothesize that ET-1 also plays a role in the mechanism of meningioma tumorigenesis. Still taking into account the potential role of other growth factors, we can speculate that ET-A receptors may provide a potential target for a therapy in meningiomas which are nonresectable or progress after initial surgical treatment.
